Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer
| Autor: | Jérôme Barrière, Daniel Re, Michel Carles, Frederic Peyrade |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cancer Research COVID-19 Vaccines Time Factors Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Third dose Disease medicine.disease_cause Antibodies Viral Risk Assessment 03 medical and health sciences Current Perspective 0302 clinical medicine Immune system Tumours Immunogenicity Vaccine Risk Factors Cause of Death Neoplasms Pandemic Medicine Humans Coronavirus Cancer business.industry Immunogenicity Heterologous prime-boost vaccination Vaccination COVID-19 ARNm medicine.disease Immunity Humoral Hospitalization 030104 developmental biology SARS-CoV-2 vaccination Treatment Outcome Oncology 030220 oncology & carcinogenesis Immunology Double-dose business Vaccine |
| Zdroj: | European Journal of Cancer |
| ISSN: | 1879-0852 0959-8049 |
| Popis: | A higher risk of death from coronavirus disease 19 has been shown for patients with solid cancers or haematological malignancies (HM). Thanks to the accelerated development of anti-SARS-SoV-2 vaccines in less than a year since the start of the global pandemic, patients with cancer were quickly prioritised in early 2021 for vaccination, however dependent on the very unequal availability at the global level. Impaired immunogenicity of SARS-CoV-2 mRNA vaccines in immunocompromised patients was rapidly reported as early as April 2021, although the vaccination fortunately appears to be generally effective without increasing the spacing. Worryingly, the humoral response of the SARS-CoV-2 vaccination is, however, considered insufficient in patients followed for HM, in particular when they are on anti-CD20 treatment. Thus, improving vaccination coverage by strengthening immune stimulation should be evaluated in patients under active treatment against cancer. Here, we discuss three different approaches: a third dose of early vaccine (repeated immune stimulation), heterologous prime-boost vaccination (multimodal immune stimulation) and a double-dose strategy (maximisation of immune response). Dedicated therapeutic trials, currently almost non-existent, seem rapidly necessary. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect